Epidemiology and unmet needs in hypertension

Journal of Managed Care Pharmacy

Volumn 13, Issue 8 SUPPL. B, 2007, Pages

  Flack, John M ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Hypertension; Hypertensive agents; Vascular disease

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ISRADIPINE; LISINOPRIL; PLACEBO; RENIN INHIBITOR;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; EVENING DOSAGE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; LIFESTYLE MODIFICATION; MICROANGIOPATHY; MONOTHERAPY; MORNING DOSAGE; PATIENT COMPLIANCE; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW; STROKE;

EID: 36248942124     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s8-a.2     Document Type: Review

References (41)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
2. Flack JM, Gardin JM, Yunis C, Liu K, for the CARDIA Research Group. Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study. Am Heart J. 1999;138(pt 1):856-64.
3. Flack JM, Neaton J, Grimm R Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation. [serial online]. November 1, 1995;92(9):2437-45. http://circ.ahajournals.org/cgi/ content/full/92/9/2437. Accessed May 15, 2007.
4. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis. 1993;21(suppl 1):S31-S40.
5. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-24.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-64.
8. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007;13(8)(suppl b):S34-S39.
9. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-69.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
11. Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005;96:1530-36.
12. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
14. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
15. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
16. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-25.
17. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141-47.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
19. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. Lancet. 2002;360:1903-13.
20. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-63.
21. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345-51.
22. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-45. Available at: http://www.amcp.org/data/jmcp/Research_239-245.pdf.
23. Burnier M, Vincze G, Kristanto P, Vrijens B. Adherence to prescribed once daily anti-hypertensive drug treatments: analysis of 4783 patients' electronically compiled dosing histories. Abstract presented at: European Society of Cardiology Congress Annual Meeting; September 1-5, 2007; Vienna, Austria.
24. Zemel MB, Richards J, Milstead A, Campbell P. Effects of calcium and dairy on body composition and weight loss in African-American adults. Obes Res. 2005;13:1218-25.
25. Zemel MB, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy augmentation of total and central fat loss in obese subjects. Int J Obes. 2005;29:391-97.
26. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
28. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-41.
29. Atlas SA. The renin-angiotensin aldesterone system: pathophsiological-role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8)(suppl b):S9-S20.
30. Chrysant SG, Weder AB, McCarron DA, et al. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens. 2000;13:1180-88.
31. Price DA, Fisher NDL, Osei SY, Lansang MC, Hollenberg NK. Renal perfusion and function in healthy African Americans. Kidney Int. 2001;59:1037-43.
32. Boddi M, Poggesi L, Coppo M, et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension. 1998;31:836-42.
33. Campese VM, Tawadrous M, Bigazzi R, et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. [serial online]. September 1996;28(3):335-40. http://hyper.ahajournals.org/cgi/content/full/28/3/335. Accessed May 15, 2007.
34. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43:566-72.
35. Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension. 2004;43:1202-07.
36. Tekturna (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2007.
37. Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-63.
38. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
39. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-29.
40. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-26.
41. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm. 2007;13(8)(suppl b):S21-S33.